负债率近416% 征祥医药递表港交所

Core Viewpoint - Zhengxiang Pharmaceutical is heavily indebted and is betting its future on a new flu drug while initiating its Hong Kong IPO process to alleviate financial pressure and seek funding for development [1][3]. Financial Performance - For the full year of 2024 and the first three quarters of 2025, Zhengxiang Pharmaceutical's revenue is projected to be 0 and 355,000 yuan respectively, primarily from drug registration assistance services rather than product sales [2]. - The company has incurred cumulative losses of nearly 300 million yuan during the same period, with R&D costs of 100 million yuan and 81.61 million yuan for 2024 and the first three quarters of 2025 respectively, leading to losses of 145 million yuan for both periods [2]. - Operating cash flow has been negative, with net cash used in operating activities amounting to 106 million yuan and 90.87 million yuan during the reporting periods [3]. Debt Situation - As of the end of September 2025, Zhengxiang Pharmaceutical's total liabilities are approximately 1.26 billion yuan, with a net debt of about 956 million yuan and a debt-to-asset ratio of 415.84% [3]. - The net current liabilities increased from 761 million yuan at the end of 2024 to 903 million yuan by September 2025, attributed to an increase in redemption liabilities and other payables [3]. Market Competition - The flu antiviral drug market in China is projected to reach 5.7 billion yuan in 2024, with expectations to grow to 13.6 billion yuan by 2035, indicating a highly competitive environment [4]. - Zhengxiang Pharmaceutical's core product, Marcilosavir, faces significant competition from established products, with pricing strategies not favoring its market entry [4][6]. - Competitors like Qingfeng Pharmaceutical and Zhongsheng Pharmaceutical have already launched their flu drugs and gained market access, while Zhengxiang's product is lagging in commercialization [5][6]. Strategic Initiatives - Zhengxiang Pharmaceutical is seeking to differentiate itself by expanding the indications for Marcilosavir and submitting a New Drug Application (NDA) for treating flu in adolescents [6]. - The company aims to find new growth points through differentiated formulations and indications, although the challenge remains significant due to established competitors [6].